Taysha Gene Therapies, Inc.
General ticker "TSHA" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $615.0M (TTM average)
Taysha Gene Therapies, Inc. follows the US Stock Market performance with the rate: 51.1%.
Estimated limits based on current volatility of 5.9%: low 4.31$, high 4.85$
Factors to consider:
- Total employees count: 73 (+40.4%) as of 2024
- Top business risk factors: Insufficient funding, Economic downturns and volatility, Market competition, Intellectual property risks, Manufacturing risks
- Current price 77.9% above estimated high
- Earnings for 9 months up through Q3 exceed our estimates
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2024-12-31 to 2026-12-31
- 2024-12-31 to 2025-12-31 estimated range: [1.11$, 2.84$]
- 2025-12-31 to 2026-12-31 estimated range: [0.87$, 2.29$]
Financial Metrics affecting the TSHA estimates:
- Positive: with PPE of -5.2 at the end of fiscal year the price was low
- Negative: negative Operating income
- Negative: Operating cash flow per share per price, % of -17.95 <= 0.33
- Negative: negative Industry operating cash flow (median)
- Positive: 41.86 < Shareholder equity ratio, % of 44.60 <= 63.39
- Positive: Investing cash flow per share per price, % of -0.08 > -0.66
- Positive: Industry inventory ratio change (median), % of 0 <= 0
- Negative: negative Net income
Short-term TSHA quotes
Long-term TSHA plot with estimates
Financial data
| YTD | 2022-12-31 | 2023-12-31 | 2024-12-31 |
|---|---|---|---|
| Operating Revenue | $2.50MM | $15.45MM | $8.33MM |
| Operating Expenses | $164.95MM | $87.89MM | $99.79MM |
| Operating Income | $-162.45MM | $-72.44MM | $-91.46MM |
| Non-Operating Income | $-3.57MM | $-39.13MM | $2.16MM |
| Interest Expense | $3.80MM | $5.00MM | $0.10MM |
| R&D Expense | $91.17MM | $56.78MM | $66.00MM |
| Income(Loss) | $-166.01MM | $-111.57MM | $-89.30MM |
| Profit(Loss)* | $-166.01MM | $-111.57MM | $-89.30MM |
| Stockholders Equity | $0.95MM | $74.94MM | $71.53MM |
| Assets | $126.28MM | $172.73MM | $160.36MM |
| Operating Cash Flow | $-88.39MM | $-73.02MM | $-81.22MM |
| Capital expenditure | $24.87MM | $7.37MM | $0.37MM |
| Investing Cash Flow | $-24.93MM | $-7.35MM | $-0.36MM |
| Financing Cash Flow | $52.10MM | $136.39MM | $76.68MM |
| Earnings Per Share** | $-3.78 | $-0.96 | $-0.36 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.